Anti-Rheumatic Drugs - Egypt | Statista Market Forecast

In Egypt, the revenue of the Anti-Rheumatic Drugs market is forecasted to reach US$30.89m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 2.81%, leading to a market volume of US$35.49m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, with US$34.70bn in 2024.
Egypt's anti-rheumatic drug market is experiencing a surge in demand due to the country's aging population and increasing prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Egypt has been on the rise in recent years.

Customer preferences: Egypt has a population of over 100 million people, with a significant proportion being elderly citizens. This demographic is more susceptible to rheumatic diseases, which has led to an increase in demand for Anti-Rheumatic Drugs. Additionally, the high prevalence of obesity and sedentary lifestyles has contributed to the rise in rheumatic diseases among the population.

Trends in the market: The Egyptian government has been investing heavily in healthcare infrastructure, which has improved access to healthcare services across the country. This has led to an increase in the number of patients being diagnosed with rheumatic diseases and subsequently, an increase in the demand for Anti-Rheumatic Drugs. Furthermore, the availability of generic drugs in the market has made treatment more affordable for patients.

Local special circumstances: Egypt has a large pharmaceutical industry, with many local manufacturers producing generic Anti-Rheumatic Drugs. This has led to increased competition in the market, resulting in lower prices for consumers. However, the quality of these drugs has been a concern for patients, leading to a preference for branded drugs.

Underlying macroeconomic factors: The Egyptian economy has been growing steadily in recent years, with a focus on diversifying the economy beyond oil and gas. This has led to increased investment in the healthcare sector, which has benefited the Anti-Rheumatic Drugs market. However, the COVID-19 pandemic has had a significant impact on the economy, leading to a decrease in disposable income for many Egyptians. This has resulted in a shift towards more affordable generic drugs, impacting the sales of branded Anti-Rheumatic Drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.